In short
This article discusses the ongoing clinical trial of Ruxotemitide (also known as LTX-315) in combination with pembrolizumab for patients with advanced melanoma. The study, called NeoLIPA, aims to evaluate the effectiveness and safety of this treatment approach in patients with resectable stage III-IV melanoma before surgery. We'll explore the trial's objectives, eligibility criteria, and potential outcomes for patients with this serious skin cancer.
At a glance
- Study Name
- NeoLIPA
- Study Type
- Phase II, open-label, single-arm
- Main Drug
- Ruxotemitide (LTX-315)
- Combination Drug
- Pembrolizumab
- Target Condition
- Resectable stage III-IV melanoma
- Primary Endpoint
- Rate of pathologic complete response (pCR)
- Key Eligibility
- Adults with confirmed, resectable stage III-IV melanoma
- Treatment Approach
- Neoadjuvant (before surgery)
- Ruxotemitide Administration
- Intratumoral injection
- Max Treatment Period
- 5 days
What is RUXOTEMITIDE?
RUXOTEMITIDE, also known by its sponsor product code LTX-315, is an investigational drug being studied for the treatment of advanced melanoma. It is a protein-based medication that is administered as an injection. This drug is currently being tested in clinical trials to evaluate its effectiveness and safety in treating patients with advanced stages of melanoma.
Medical Conditions Treated
RUXOTEMITIDE is being studied specifically for patients with clinically detectable and resectable stage III-IV melanoma. Melanoma is a type of skin cancer that can be very serious if it spreads to other parts of the body. The stages mentioned in the study refer to:
- Stage III melanoma: Cancer has spread to nearby lymph nodes but not to distant parts of the body.
- Stage IV melanoma: Cancer has spread to distant parts of the body, such as the lungs, liver, or brain.
The term "resectable" means that the cancer can be surgically removed, which is an important factor in the treatment plan.
How RUXOTEMITIDE is Administered
RUXOTEMITIDE is administered through intratumoral use, which means it is injected directly into the tumor. This method of administration allows the drug to target the cancer cells more directly. The maximum daily dose amount is 40 mg/g, with a maximum total dose amount of 200 mg over a treatment period of up to 5 days.
Clinical Trial Details
The clinical trial for RUXOTEMITIDE, known as NeoLIPA, is a phase II open-label study that combines RUXOTEMITIDE (LTX-315) with another drug called pembrolizumab. This combination is being tested as a neoadjuvant treatment, which means it's given before the main treatment (in this case, surgery) to potentially improve outcomes.
The main goal of the study is to measure the tumor response to this neoadjuvant treatment, specifically looking at the rate of pathological complete response (pCR). This means the researchers want to see if the treatment can eliminate all detectable cancer cells before surgery.
Eligibility Criteria
To participate in this clinical trial, patients must meet certain criteria. Some key eligibility factors include:
- Being 18 years of age or older
- Having confirmed stage III-IV melanoma that can be surgically removed
- Having at least one tumor that can be injected with the study drug
- Being in generally good health and able to perform daily activities
There are also factors that would exclude someone from participating, such as having certain other medical conditions or having received specific previous treatments.
Potential Benefits
While the effectiveness of RUXOTEMITIDE is still being studied, the researchers hope to see several potential benefits, including:
- Reduction in tumor size before surgery
- Improved success of surgery
- Longer time without the cancer returning after treatment
- Better overall survival rates
It's important to note that these are potential benefits, and the actual results of the study are not yet known.
Safety Considerations
As with any medical treatment, safety is a crucial consideration. The clinical trial is designed to carefully monitor for any side effects or adverse events related to the treatment. Patients in the study will be closely watched for any reactions to RUXOTEMITIDE or the combination treatment with pembrolizumab.
It's important for patients to discuss all potential risks and benefits with their healthcare provider before considering participation in a clinical trial.